Mirati (MRTX) Q2 Loss Narrower Than Expected, Sales Beat

This article was originally published on Nasdaq

Mirati Therapeutics MRTX reported a loss of $3.18 per share in second-quarter 2022, narrower than the Zacks Consensus Estimate of a loss of $3.53 and the year-ago quarter’s loss of $3.23.

Responses